Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

October 12, 2017: By Jon Swedien

AlconAlcon announced Sept. 29 that its AcrySof intraocular lenses (IOLs) have been implanted more than 100 million times.

In celebration, Alcon launched its “100 Million Moments Made” campaign, which includes resources designed to showcase the accomplishment in markets around the globe, the Fort Worth, Texas, company said.

The first recorded implantation of an AcrySof IOL was in the UK in 1990. Since then, the platform has grown to include solutions for correcting astigmatism (AcrySof IQ Toric) and presbyopia (AcrySof IQ ReSTOR and PanOptix), Alcon said.

The AcrySof family of IOLs includes brands available in approximately 120 markets: AcrySof IQ, AcrySof IQ Toric, AcrySof IQ ReSTOR, AcrySof IQ ReSTOR Toric, AcrySof IQ PanOptix, and AcrySof IQ PanOptix Toric.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

Allergan Appoints Matthew Walsh as CFO

Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023